Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson's Disease Dementia: A 36 Months Follow Up Study.
Parkinson's disease dementia
cholinergic networks
deep brain stimulation
dementia
nucleus basalis of Meynert
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
25
07
2021
revised:
07
04
2022
accepted:
08
05
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
Degeneration of the nucleus basalis of Meynert (NBM) and cortical cholinergic dysfunction are hallmarks of Parkinson's disease dementia (PDD). There is no effective therapy for PDD. Deep brain stimulation of the NBM (NBM-DBS) has been trialed as a potential treatment. Our primary aim was to evaluate the sustained tolerability of NBM-DBS in PDD, and its impact on global cognition, behavioral symptoms, quality of life and caregiver burden and distress. Second, we aimed to determine whether baseline measures of arousal, alertness, and attention were predictive of the three year response to NBM-DBS in PDD patients. Five of the six PDD patients who completed the baseline assessment participated in a 3 year follow up assessment. We assessed the participants after three years of NBM-DBS on the Mini Mental State Examination, Dementia Rating Scale-2, Blessed Dementia Rating Scale, Neuropsychiatric Inventory, and the SF36. The five patients showed varying trajectories of cognitive decline, with two showing a slower progression over the three-year follow-up period. A slower progression of decline on global cognition was associated with higher baseline accuracy on the Posner covert orienting of attention test, and less daytime sleepiness. Whether slower progression of cognitive decline in two patients was in any way related to individual variability in responsiveness to NBM-DBS requires confirmation in a larger series including an unoperated PDD control group. Higher accuracy in covertly orienting attention and better sleep quality at baseline were associated with better cognitive outcomes at 36 months assessment. These results require validation in future studies with larger samples.
Sections du résumé
Background
UNASSIGNED
Degeneration of the nucleus basalis of Meynert (NBM) and cortical cholinergic dysfunction are hallmarks of Parkinson's disease dementia (PDD). There is no effective therapy for PDD. Deep brain stimulation of the NBM (NBM-DBS) has been trialed as a potential treatment.
Objective
UNASSIGNED
Our primary aim was to evaluate the sustained tolerability of NBM-DBS in PDD, and its impact on global cognition, behavioral symptoms, quality of life and caregiver burden and distress. Second, we aimed to determine whether baseline measures of arousal, alertness, and attention were predictive of the three year response to NBM-DBS in PDD patients.
Methods
UNASSIGNED
Five of the six PDD patients who completed the baseline assessment participated in a 3 year follow up assessment. We assessed the participants after three years of NBM-DBS on the Mini Mental State Examination, Dementia Rating Scale-2, Blessed Dementia Rating Scale, Neuropsychiatric Inventory, and the SF36.
Results
UNASSIGNED
The five patients showed varying trajectories of cognitive decline, with two showing a slower progression over the three-year follow-up period. A slower progression of decline on global cognition was associated with higher baseline accuracy on the Posner covert orienting of attention test, and less daytime sleepiness.
Conclusions
UNASSIGNED
Whether slower progression of cognitive decline in two patients was in any way related to individual variability in responsiveness to NBM-DBS requires confirmation in a larger series including an unoperated PDD control group. Higher accuracy in covertly orienting attention and better sleep quality at baseline were associated with better cognitive outcomes at 36 months assessment. These results require validation in future studies with larger samples.
Identifiants
pubmed: 35937485
doi: 10.1002/mdc3.13510
pii: MDC313510
pmc: PMC9346244
doi:
Types de publication
Journal Article
Langues
eng
Pagination
765-774Informations de copyright
© 2022 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.
Références
Neuromodulation. 2018 Feb;21(2):184-190
pubmed: 28653404
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504
pubmed: 22419314
Trends Neurosci. 1999 Jun;22(6):273-80
pubmed: 10354606
Curr Biol. 2017 Sep 11;27(17):2640-2646.e4
pubmed: 28823679
Behav Brain Res. 1996 Feb;75(1-2):13-25
pubmed: 8800650
Mol Psychiatry. 2015 Mar;20(3):353-60
pubmed: 24798585
Lancet Neurol. 2018 Nov;17(11):928-929
pubmed: 30287052
Brain. 2018 Jan 1;141(1):7-10
pubmed: 29325047
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
Br J Psychiatry. 1968 Jul;114(512):797-811
pubmed: 5662937
Parkinsonism Relat Disord. 2018 May;50:99-103
pubmed: 29429645
BMJ. 1993 May 29;306(6890):1437-40
pubmed: 8518639
Mov Disord. 2007 Dec;22(16):2314-24
pubmed: 18098298
Arch Neurol. 2004 Dec;61(12):1906-11
pubmed: 15596611
Lancet Neurol. 2010 Dec;9(12):1200-1213
pubmed: 20880750
J Neurosci. 2019 Aug 7;39(32):6315-6324
pubmed: 31209175
J Neurosci. 1994 Jan;14(1):167-86
pubmed: 8283232
Mov Disord. 2010 Jul 15;25(9):1170-6
pubmed: 20310053
J Neurol Sci. 1983 May;59(2):277-89
pubmed: 6854353
Arch Gen Psychiatry. 1983 Jul;40(7):812
pubmed: 6860082
Neuroscience. 1992;47(2):251-64
pubmed: 1641123
Gerontologist. 1980 Dec;20(6):649-55
pubmed: 7203086
Science. 2016 Nov 25;354(6315):1004-1008
pubmed: 27885006
J Neurosci. 1992 Dec;12(12):4701-11
pubmed: 1361197
Brain Stimul. 2015 Jul-Aug;8(4):838-9
pubmed: 25991080
Brain Stimul. 2016 Sep-Oct;9(5):799-800
pubmed: 27522168
Arch Neurol. 2009 Jun;66(6):781-5
pubmed: 19506141
Behav Brain Res. 1989 Dec 1;35(3):221-40
pubmed: 2688683
J Neurophysiol. 2012 Apr;107(7):2008-19
pubmed: 22236708
JAMA Neurol. 2018 Feb 1;75(2):169-178
pubmed: 29255885
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2676-88
pubmed: 24035740
Sleep Med. 2013 Aug;14(8):744-8
pubmed: 23347909
Clin Neurophysiol. 2006 Sep;117(9):1885-901
pubmed: 16581292
J Neurosci. 1988 Nov;8(11):4007-26
pubmed: 3183710
Mov Disord. 2008 Apr 30;23(6):837-44
pubmed: 18307261
Brain. 2015 Jun;138(Pt 6):1454-76
pubmed: 25888551
Brain. 2018 Jan 1;141(1):165-176
pubmed: 29228203
J Neurosci. 2004 Nov 17;24(46):10369-78
pubmed: 15548651
J Comp Neurol. 2011 Apr 1;519(5):933-56
pubmed: 21280045